The Significant Impacts of Interleukin-8 Genotypes on the Risk of Colorectal Cancer in Taiwan
by
Chia-Wen Tsai
1,2,3,†,
Wen-Shin Chang
1,2,3,†,
Te-Cheng Yueh
3,4,5,
Yun-Chi Wang
1,3,
Yu-Ting Chin
1,3,
Mei-Due Yang
3,6,
Yi-Chih Hung
1,3,
Mei-Chin Mong
7,
Ya-Chen Yang
7,
Jian Gu
2,* and
Da-Tian Bau
1,3,8,* 1
Graduate Institute of Biomedical Sciences, China Medical University, Taichung 404333, Taiwan
2
Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
3
Terry Fox Cancer Research Laboratory, Department of Medical Research, China Medical University Hospital, Taichung 404327, Taiwan
4
Division of Colon and Rectal Surgery, Department of Surgery, Taichung Armed Forces General Hospital, Taichung 41152, Taiwan
5
National Defense Medical Center, Taipei 11490, Taiwan
6
Department of General Surgery, China Medical University Hospital, Taichung 404332, Taiwan
7
Department of Food Nutrition and Health Biotechnology, Asia University, Taichung 41354, Taiwan
8
Department of Bioinformatics and Medical Engineering, Asia University, Taichung 41354, Taiwan
*
Authors to whom correspondence should be addressed.
†
These authors contributed equally to this study.
Cancers 2023, 15(20), 4921; https://doi.org/10.3390/cancers15204921
Submission received: 6 September 2023
/
Revised: 29 September 2023
/
Accepted: 4 October 2023
/
Published: 10 October 2023
(This article belongs to the Special Issue Crosstalk between Inflammation and Carcinogenesis)
Abstract
:Simple Summary
The objective of this study was to investigate the association between IL-8 rs4073, rs2227306, rs2227543, and rs1126647 genotypes and the risk of colorectal cancer (CRC) in the Taiwanese population. Our findings reveal that the A allele and AA genotype of IL-8 rs4073 are significantly associated with an increased susceptibility to CRC in Taiwan. This observation provides further evidence of the complex interplay between inflammation and carcinogenesis in CRC development. Furthermore, individuals with the AA genotype exhibit significantly higher levels of serum IL-8 expression. Combining IL-8 rs4073 genotyping with the assessment of IL-8 levels may have potential benefits in terms of the precise risk evaluation and early detection of CRC among patients.
Abstract
Interleukin-8 (IL-8), a pro-inflammatory cytokine, is upregulated in CRC and plays an important role in its development and progression. Genetic variants in the IL-8 gene may impact the risk of CRC by modulating IL-8 levels. Our primary objective was to investigate the role of IL-8 genotypes in the development of CRC. To accomplish this, we employed the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method to analyze the genotypes of IL-8 rs4017, rs2227306, rs2227543, and rs1126647 in 362 CRC patients and 362 controls. Additionally, we evaluated the interactions between these genotypes and factors such as age, gender, smoking, alcohol consumption, and body mass index (BMI) status in relation to the risk of CRC. Furthermore, we utilized quantitative reverse transcription-PCR to measure the serum IL-8. The results demonstrated a significant difference in the distribution of rs4017 genotypes between the control and case groups (p for trend = 0.0059). Logistic regression analysis revealed that individuals with variant AA genotype had a 1.92-fold higher CRC risk (95% confidence interval [CI] = 1.28–2.89, p = 0.0023). Moreover, carriers of the IL-8 rs4017 AT + AA genotypes exhibited a significant association with CRC risk (odds ratio [OR] = 1.39, 95% CI = 1.02–1.91, p = 0.0460). Additionally, individuals with IL-8 rs4017 AA genotype displayed significantly elevated serum IL-8 compared to those with TT genotype at a 1.73–fold level (p < 0.0001), indicating a correlation between genotype and phenotype. In conclusion, the genotypes of IL-8 rs4017, along with their associated expression levels, can potentially serve as predictive markers for the risk of CRC.
1. Introduction
Colorectal cancer (CRC) is a prevalent malignancy worldwide, ranking third in terms of incidence and second in cancer-related mortality [1]. Over the past two decades, significant progress has been made in CRC prognosis due to a deeper understanding of the biological mechanisms underlying colorectal carcinogenesis and tumor progression, along with advancements in treatment options [2]. In Taiwan, CRC is a major health concern, exhibiting the highest incidence rate among all cancer types and ranking third in terms of mortality, following lung and liver cancer. Given that 15–20% of CRC cases have a familial cancer history [3,4], genetic factors are considered to play a critical role in CRC etiology. Despite the identification of numerous genetic biomarkers for CRC in recent years [5,6,7,8], there remains great interest in identifying additional genetic susceptibility factors and exploring the interactions between genetic factors and other risk factors. These biomarkers included those that played important roles in extracellular microenvironment regulation [5,7], oncogenic miRNAs [6], DNA methylation homeostasis [8], etc. An enhanced understanding of the genetic contributions to CRC can assist scientists in developing more precise and targeted approaches to cancer prevention and therapy.
Chemokines play significant roles in CRC development and progression [9]. IL-8, encoded by the CXCL8 (chemokine C-X-C motif ligand 8) gene, stands out as a pro-angiogenic and pro-inflammatory chemokine. Previous studies have reported an increased expression of IL-8 mRNA in inflammatory colorectal polyps and advanced CRC tissues [10,11,12,13]. Through its interaction with receptors on target cells, IL-8 triggers specific downstream signaling pathways, including the phosphoinositide 3-kinase [PI3K] and mitogen-activated protein kinase [MAPK] cascades, consequently promoting various pro-tumoral phenotypes (reviewed in [10,11]). One of the well-established effects of tumor-derived IL-8 is VEGF-independent angiogenesis [11]. Additionally, IL-8 contributes to both the epithelial-to-mesenchymal transition (EMT) and the generation and maintenance of cancer stem cells [11]. Furthermore, immune cell populations also contribute to the production of IL-8, both within the tumor microenvironment (TME) and systemically [11]. Notably, IL-8 plays a pivotal role as a chemoattractant for monocytes/macrophages within the tumor tissue [11]. Moreover, IL-8 derived from tumor-associated macrophages enhances the metastatic behavior of CRC cells [10,11].
Single nucleotide polymorphisms (SNPs) are common subtle genetic variations that can impact the expression and/or function of specific genes, thereby contributing to tumorigenesis. While the biological role of IL-8 in cancer cell regulation and the tumor microenvironment has been well characterized, the significance of IL-8 genotypes in CRC etiology remains unclear. Several SNPs within the IL-8 gene, including T−251A (rs4073), C + 781T (rs2227306), C + 1633T (rs2227543), and A + 2767T (rs1126647), have been widely studied in their associations with different cancers (summarized in [14]); in particular, the A allele of IL-8 rs4073, located in the promoter region of IL-8, is associated with the overexpression of the IL-8 protein [15,16,17]. Since IL-8 is a pro-angiogenic, pro-inflammatory, and pro-tumoral chemokine, it follows that this SNP may be predisposed to CRC. In this study, we aim to investigate the contribution of the rs4073, rs2227306, rs2227543, and rs1126647 genotypes of IL-8 to the risk of CRC in Taiwan. This investigation may provide further evidence supporting the interplay between inflammation and carcinogenesis. Moreover, our objective is to provide a comprehensive summary that enables readers to gain a thorough understanding of the significance of IL-8 genotypes in predicting the risk of CRC. The physical map for the SNPs investigated in this study is shown in Figure 1.
2. Materials and Methods
2.1. Study Population
The recruitment of CRC cases and healthy controls followed the methodology described in our previous publications [7,8]. In brief, 362 histologically confirmed CRC cases were recruited from the China Medical University Hospital (CMUH), and comprehensive pathological data were documented. Among them, 203 (56.1%) were males and 159 (43.9%) were females; a total of 95 (26.2%) were 60 years or younger, and 267 (73.8%) were older than 60 years. The stage distribution of the cases was as follows: 94 (26.0%) for stage 1, 72 (19.9%) for stage 2, 134 (37.0%) for stage 3, and 62 (17.1%) for stage 4. The inclusion criteria for the CRC case group included being over 30 years of age, having had their first CRC diagnosis within 6 months, and a willingness to participate in this study and donate blood samples. The inclusion criteria for the controls were as follows: not having a history of any malignancy, no diseases affecting dietary intake, no use of drugs that affected body weight, and a willingness to participate in this study. The same number of age- and gender-matched healthy subjects were chosen from the Health Examination Cohort database of the China Medical University Hospital. Some control participants were excluded and replaced with more properly recorded ones due to insufficient or incorrect data (n = 4) or a diagnosis of malignancy during the study (n = 8). All the participants are Taiwan citizens with a National Health Insurance card. The study protocol was approved by the Institutional Review Board of CMUH (approval code: DMR99-IRB-108).
2.2. Genotyping Methodology of IL-8 Polymorphisms
Genomic DNA was isolated from the blood samples using a Qiagen kit (Qiagen, Chatsworth, CA, USA). The genotyping of IL-8 rs4073, rs2227306, rs2227543, and rs1126647 was performed using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method, as previously reported [18]. During the initial development of these assays, we sent ten DNA samples for DNA sequencing (AllBio, Taichung, Taiwan, ROC) with representative genotypes, and the results of the PCR-RFLP and sequencing were 100% concordant.
The PCR was performed in a PCR Thermocycler (Bio-RAD, Hercules, CA, USA) under the following conditions: initial denaturation at 94 °C for 5 min, followed by denaturation at 94 °C for 30 s, annealing at 64 °C for 40 s, and extension at 72 °C for 45 s. After 35 PCR cycles, a final extension step was performed at 72 °C for 10 min. The sequences of forward and reverse primers for IL-8 rs4073, rs2227306, rs2227543, and rs1126647 are summarized in Table 1. The PCR products for rs4073, rs2227306, rs2227543, and rs1126647 were visualized using 3% agarose gel electrophoresis to confirm its successful amplification. Subsequently, the PCR products were digested with Mfe I, EcoR I, Nla III, and BstZ17 I, and the resulting digestion fragments were further confirmed by 4% agarose gel electrophoresis.
2.3. Quantitative Reverse Transcription Polymerase Chain Reaction for Examining IL-8 Transcriptional Expression
To assess the relationship between IL-8 mRNA expression and IL-8 SNPs, a total of 34 samples obtained from healthy controls with different genotypes were used. Total RNA was extracted from these samples using Trizol Reagent (Invitrogen, Carlsbad, CA, USA). The quantity of the total RNA was measured using a real-time quantitative RT-PCR instrument (FTC-3000, Funglyn Biotech Inc., Richmond Hill, ON, Canada). Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was employed as an internal quantitative control. For the amplification of IL-8 and GAPDH, the forward and reverse primers are summarized in Table 1 [18]. Fold changes were normalized based on the expression levels of GAPDH, and each assay was performed at least in triplicate.
2.4. Statistical Analysis
To compare the ages (a continuous variable) between the case and control groups, we employed the unpaired Student’s t-test. The distributions of gender, personal habits, different genotypes, and alleles among the subgroups were assessed using Pearson’s chi-square test. The associations between different genotypes and the risk of CRC were evaluated by calculating individual odds ratios (ORs) along with their corresponding 95% confidence intervals (CIs). Additionally, the expression levels among different genotypes were compared using the unpaired Student’s t-test. All statistical analyses were performed using the SPSS software version 12. Statistical significance was defined as a p-value less than 0.05.
3. Results
3.1. Characteristics of Study Population
The demographic and clinical characteristics of the cases and controls are presented in Table 2. The controls were matched 1:1 to the cases in terms of age and gender. There were no significant differences in the distribution of smoking frequency (p = 0.543), alcohol consumption (p = 0.441), and BMI (p = 0.181) between the case and control groups (Table 2).
3.2. Interluekin-8 Rs4073 Genotypes Were Specifically Associated with CRC Risk in Taiwan
The genotypes of IL-8 rs4073, rs2227306, rs2227543, and rs1126647 in the control groups were consistent with the expected frequencies based on the Hardy–Weinberg equation (all p > 0.05). A significant association was observed between rs4073 genotypes and the risk of CRC. Compared to the wild-type TT genotype, individuals carrying the heterozygous variant genotype AT had an odds ratio (OR) of 1.20 (95% confidence interval [CI] = 0.85–1.68, p = 0.3407), while those carrying the homozygous variant AA genotype had a 1.92-fold increased risk of CRC (95% CI = 1.28–2.89, p = 0.0023) (p for trend = 0.0059). Individuals carrying the variant genotypes (AT + AA) had a 1.39-fold increased risk of CRC (95% CI = 1.02–1.91, p = 0.0460) (Table 3). However, no significant associations were found for rs2227306, rs2227543, or rs1126647 genotypes with the risk of CRC in any of the analyzed models (Table 3).
3.3. Validation of the IL-8 Alleles with CRC Risk
Table 4 presents the allelic test results for rs4073, rs2227306, rs2227543, and rs1126647 polymorphic sites in relation to CRC risk. Consistent with the findings in Table 3, the frequency of the A allele in rs4073 was significantly higher in the CRC patient group (49.4%) than the control group (41.2%). Individuals carrying the variant A allele had a 1.4-fold (95% CI = 1.14–1.72, p = 0.0018) increased risk of CRC. However, for rs2227306, rs2227543, and rs1126647, the frequencies of the variant alleles did not show significant differences between the cases and controls (Table 4).
3.4. Stratified Analyses of Interluekin-8 Rs4073 Genotypes by Age, Gender, Smoking, Alcohol Drinking, and BMI Status
We conducted stratified analyses to examine the association between IL-8 rs4073 genotype and the risk of CRC based on age, gender, smoking, alcohol drinking, and BMI status (Table 5). In general, significant associations between the IL-8 rs4073 genotype and CRC risk were observed in all the strata, except for the younger, smoker, and drinker subgroups. In the younger (OR = 1.78, 95% CI = 0.80–3.93, p = 0.2197), smoker (OR = 1.69, 95% CI = 0.72–3.95, p = 0.3195), and drinker (OR = 3.00, 95% CI = 0.79–11.46, p = 0.1862) subgroups, the risk associated with the AA genotype did not reach statistical significance, possibly due to the limited sample size (Table 5).
3.5. Genotype–Phenotype Correlation of IL-8 among Controls
We conducted further investigations on the serum expression levels of IL-8 and their correlation with IL-8 rs4073 genotypes. A total of thirty-four serum samples from the control group were collected. Among these samples, 11 individuals had the TT genotype, 17 had the AT genotype, and 6 had the AA genotype at IL-8 rs4073. We observed a significant increase of 1.73-fold in serum IL-8 levels in individuals with the homozygous variant genotype AA compared to those with the wild-type TT genotype (p < 0.0001) (Figure 2A). Furthermore, when combining the AT and AA genotypes, the expression of IL-8 remained significantly higher compared to the wild-type TT genotype (p = 0.0446) (Figure 2B).
4. Discussion
In this study, we found that the variant genotypes and allele of IL-8 rs4073 were significantly associated with increased risks of CRC in Taiwan (Table 3 and Table 4). The other three SNPs—rs2227306, rs2227543, and rs1126647—were not associated with CRC risks in Taiwan. Furthermore, we found that the IL-8 rs4073 AA genotype is associated with a higher IL-8 expression compared to the wild-type TT genotype (Figure 2). Our findings are consistent with several previous studies that reported an association between the IL-8 rs4073 AA genotype and increased CRC risk in Caucasian populations [19,20,21] (Table 6). However, there were also conflicting results suggesting that the rs4073 AA genotype was not associated with CRC risks [22,23,24,25,26,27,28] (Table 6). The inconsistencies among these findings, despite studying comparable Caucasian populations, cannot be solely attributed to ethnic heterogeneity but may be influenced by factors such as small sample size, sampling bias, and other considerations. For instance, it is worth noting that the rs4073 genotype frequencies in studies conducted by Walczak et al. [19], Mustapha et al. [20], and Kury et al. [24] do not conform to the Hardy–Weinberg Equilibrium. Our study is the first and only one to report that the IL-8 rs4073 AA genotype can serve as a marker for CRC risk in an Asian population. Further multi-population and multi-center studies encompassing larger sample sizes and diverse ethnicities are imperative for enhancing our understanding of the role of IL-8 genotypes in the risk of CRC.
The IL-8 rs4073 genotype, located in its promoter region, may play a crucial role in determining its expression levels in circulation, which has important clinical implications for CRC. For example, Burz et al. reported that CRC patients exhibit higher levels of IL-8 compared to healthy individuals, and elevated IL-8 levels are prognostic, and predictive factors for chemotherapy [29]. Moreover, high serum IL-8 levels have been associated with the expression of specific CD4+ T cell genes in CRC patients [30]. Furthermore, Oladipo et al. demonstrated that 65.4% of CRC tumor tissues expressed IL-8 within the tumor cores, while none of the normal colorectal tissues showed detectable IL-8 expression in inflammatory cells [31]. Two meta-analyses both concluded that high IL-8 levels significantly correlated with advanced CRC stages and increased mortality risk [11,32]. Conducting investigations that specifically measure IL-8 expression among CRC patients at different stages could have significant implications for understanding tumor progression and guiding the development of specific therapeutic strategies targeting the IL-8 axis. Additionally, the routine assessment of circulating IL-8 levels could be implemented to stratify CRC patients based on different prognoses and aid in selecting the most suitable treatment approach.
In retrospective epidemiological studies, the regions where the participants are selected from may confound the association between a potential risk factor and a disease. However, our study is genetics focused. Taiwan is a relatively small country, and the genetic background of our population is fully or nearly homogeneous. In addition, the study participants were all recruited from the China Medical University Hospital, the largest medical center in central Taiwan. Taiwan has an extremely high density of hospitals, and most citizens are accustomed to seeking medical care at facilities close to them. Nearly all of our participants were from central Taiwan, mostly residing in the city of Taichung and nearby areas. The effect of different regions on the genetic susceptibility of the same ethnicity is minimal.
5. Conclusions
In summary, this study provides evidence that the A allele and AA genotype of IL-8 rs4073 are associated with an elevated risk of CRC in the Taiwanese population. The involvement of IL-8 and CRC is another piece of evidence supporting the intricate interplay between inflammation and carcinogenesis. Additionally, the AA genotype is linked to significantly higher levels of serum IL-8 expression among the control subjects. The variance of IL-8 genotypes on its expression among CRC cases needs further investigation. In combination with IL-8 rs4073 genotyping, increased IL-8 levels may benefit CRC patients by enabling more precise risk assessment and an early detection of the disease.
Author Contributions
Conceptualization: T.-C.Y., D.-T.B., C.-W.T. and W.-S.C.; Collection: M.-D.Y. and Y.-C.H.; Data curation: M.-C.M. and C.-W.T.; Genotyping: Y.-C.W., Y.-T.C. and W.-S.C.; Statistics: Y.-C.Y. and C.-W.T.; Phenotyping: D.-T.B., J.G. and W.-S.C.; Project administration: T.-C.Y. and D.-T.B.; Supervision: D.-T.B., W.-S.C. and C.-W.T.; Validation: T.-C.Y. and W.-S.C.; Writing—original draft: T.-C.Y., J.G. and C.-W.T.; Writing—review and editing, D.-T.B., J.G. and W.-S.C. All authors have read and agreed to the published version of the manuscript.
Funding
This study received significant support from the Taichung Armed Forces General Hospital (TCAFGH-D-112020) and China Medical University Hospital in collaboration with Asia University (CMU111-ASIA-03). The funders had no involvement in the study design, data collection, statistical analysis, decision to publish, or manuscript preparation.
Institutional Review Board Statement
The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the China Medical University Hospital (DMR99-IRB-108).
Informed Consent Statement
Informed consent was obtained from all subjects involved in the study.
Data Availability Statement
The genotyping results and clinical data supporting the findings of this study are available from the corresponding authors upon reasonable request via email at [email protected].
Conflicts of Interest
The authors declare no conflict of interest.
References
- Li, Q.H.; Wang, Y.Z.; Tu, J.; Liu, C.W.; Yuan, Y.J.; Lin, R.; He, W.L.; Cai, S.R.; He, Y.L.; Ye, J.N. Anti-EGFR therapy in metastatic colorectal cancer: Mechanisms and potential regimens of drug resistance. Gastroenterol. Rep. 2020, 8, 179–191. [Google Scholar] [CrossRef] [PubMed]
- Malki, A.; ElRuz, R.A.; Gupta, I.; Allouch, A.; Vranic, S.; Al Moustafa, A.E. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. Int. J. Mol. Sci. 2020, 22, 130. [Google Scholar] [CrossRef]
- Butterworth, A.S.; Higgins, J.P.; Pharoah, P. Relative and absolute risk of colorectal cancer for individuals with a family history: A meta-analysis. Eur. J. Cancer 2006, 42, 216–227. [Google Scholar] [CrossRef] [PubMed]
- Houlston, R.S.; Tomlinson, I.P. Polymorphisms and colorectal tumor risk. Gastroenterology 2001, 121, 282–301. [Google Scholar] [CrossRef] [PubMed]
- Deng, Y.; Ke, T.W.; Wang, Y.C.; Chin, Y.T.; Yueh, T.C.; Hung, Y.C.; Mong, M.C.; Yang, Y.C.; Chang, W.S.; Shen, T.C.; et al. Impact of Matrix Metalloproteinase-8 Genotypes on Colorectal Cancer Risk in Taiwan. Anticancer Res. 2023, 43, 3979–3985. [Google Scholar] [CrossRef]
- Yueh, T.C.; Wang, Y.C.; Chin, Y.T.; Hung, Y.C.; Mong, M.C.; Yang, Y.C.; Pei, J.S.; Gu, J.; Tsai, C.W.; Bau, D.T.; et al. Impact of Mir196a-2 Genotypes on Colorectal Cancer Risk in Taiwan. Int. J. Mol. Sci. 2023, 24, 11613. [Google Scholar] [CrossRef]
- Yueh, T.C.; Hung, Y.C.; Lee, H.T.; Yang, M.D.; Wang, Z.H.; Yang, Y.C.; Ke, T.W.; Pei, J.S.; Tsai, C.W.; Bau, D.T.; et al. Role of Matrix Metallopeptidase-2 Genotypes in Taiwanese Patients with Colorectal Cancer. Anticancer Res. 2022, 42, 5335–5342. [Google Scholar] [CrossRef]
- Wu, M.H.; Chen, C.H.; Chen, C.P.; Huang, T.L.; Yueh, T.C.; Wang, Z.H.; Tsai, C.W.; Pei, J.S.; Mong, M.C.; Yang, Y.C.; et al. Contribution of 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Genotypes to Colorectal Cancer in Taiwan. Anticancer Res. 2022, 42, 2375–2382. [Google Scholar] [CrossRef]
- Maryam, S.; Krukiewicz, K.; Haq, I.U.; Khan, A.A.; Yahya, G.; Cavalu, S. Interleukins (Cytokines) as Biomarkers in Colorectal Cancer: Progression, Detection, and Monitoring. J. Clin. Med. 2023, 12, 3127. [Google Scholar] [CrossRef]
- Najdaghi, S.; Razi, S.; Rezaei, N. An overview of the role of interleukin-8 in colorectal cancer. Cytokine 2020, 135, 155205. [Google Scholar] [CrossRef]
- Bazzichetto, C.; Milella, M.; Zampiva, I.; Simionato, F.; Amoreo, C.A.; Buglioni, S.; Pacelli, C.; Le Pera, L.; Colombo, T.; Bria, E.; et al. Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic Biomarker. Biomedicines 2022, 10, 2631. [Google Scholar] [CrossRef] [PubMed]
- Barbalan, A.; Streata, I.; Ivan, E.T.; Cherciu, I.; Surlin, V.; Ioana, M.; Saftoiu, A. Interleukin-8 mRNA Expression in Locally Advanced Colorectal Cancer Patients. Curr. Health Sci. J. 2017, 43, 209–213. [Google Scholar] [PubMed]
- Tamura, Y.; Ohta, H.; Torisu, S.; Yuki, M.; Yokoyama, N.; Murakami, M.; Lim, S.Y.; Osuga, T.; Morishita, K.; Nakamura, K.; et al. Markedly increased expression of interleukin-8 in the colorectal mucosa of inflammatory colorectal polyps in miniature dachshunds. Vet. Immunol. Immunopathol. 2013, 156, 32–42. [Google Scholar] [CrossRef] [PubMed]
- Zhang, M.; Fang, T.; Wang, K.; Mei, H.; Lv, Z.; Wang, F.; Cai, Z.; Liang, C. Association of polymorphisms in interleukin-8 gene with cancer risk: A meta-analysis of 22 case-control studies. OncoTargets Ther. 2016, 9, 3727–3737. [Google Scholar] [CrossRef] [PubMed]
- Araki, S.; Omori, Y.; Lyn, D.; Singh, R.K.; Meinbach, D.M.; Sandman, Y.; Lokeshwar, V.B.; Lokeshwar, B.L. Interleukin-8 is a molecular determinant of androgen independence and progression in prostate cancer. Cancer Res. 2007, 67, 6854–6862. [Google Scholar] [CrossRef]
- Hull, J.; Thomson, A.; Kwiatkowski, D. Association of respiratory syncytial virus bronchiolitis with the interleukin 8 gene region in UK families. Thorax 2000, 55, 1023–1027. [Google Scholar] [CrossRef]
- Miller, H.; Czigany, Z.; Lurje, I.; Reichelt, S.; Bednarsch, J.; Strnad, P.; Trautwein, C.; Roderburg, C.; Tacke, F.; Gaisa, N.T.; et al. Impact of Angiogenesis- and Hypoxia-Associated Polymorphisms on Tumor Recurrence in Patients with Hepatocellular Carcinoma Undergoing Surgical Resection. Cancers 2020, 12, 3826. [Google Scholar] [CrossRef]
- Huang, C.Y.; Chang, W.S.; Tsai, C.W.; Hsia, T.C.; Shen, T.C.; Bau, D.T.; Shui, H.A. The contribution of interleukin-8 genotypes and expression to nasopharyngeal cancer susceptibility in Taiwan. Medicine 2018, 97, e12135. [Google Scholar] [CrossRef]
- Walczak, A.; Przybylowska, K.; Dziki, L.; Sygut, A.; Chojnacki, C.; Chojnacki, J.; Dziki, A.; Majsterek, I. The lL-8 and IL-13 gene polymorphisms in inflammatory bowel disease and colorectal cancer. DNA Cell Biol. 2012, 31, 1431–1438. [Google Scholar] [CrossRef]
- Mustapha, M.A.; Shahpudin, S.N.; Aziz, A.A.; Ankathil, R. Risk modification of colorectal cancer susceptibility by interleukin-8 -251T>A polymorphism in Malaysians. World J. Gastroenterol. 2012, 18, 2668–2673. [Google Scholar] [CrossRef]
- Gunter, M.J.; Canzian, F.; Landi, S.; Chanock, S.J.; Sinha, R.; Rothman, N. Inflammation-related gene polymorphisms and colorectal adenoma. Cancer Epidemiol. Biomark. Prev. 2006, 15, 1126–1131. [Google Scholar] [CrossRef] [PubMed]
- Tsilidis, K.K.; Helzlsouer, K.J.; Smith, M.W.; Grinberg, V.; Hoffman-Bolton, J.; Clipp, S.L.; Visvanathan, K.; Platz, E.A. Association of common polymorphisms in IL10, and in other genes related to inflammatory response and obesity with colorectal cancer. Cancer Causes Control 2009, 20, 1739–1751. [Google Scholar] [CrossRef] [PubMed]
- Cacev, T.; Loncar, B.; Seiwerth, S.; Spaventi, S.; Kapitanovic, S. Vascular endothelial growth factor polymorphisms -1154 G/A and -460 C/T are not associated with VEGF mRNA expression and susceptibility to sporadic colon cancer. DNA Cell Biol. 2008, 27, 569–574. [Google Scholar] [CrossRef]
- Kury, S.; Buecher, B.; Robiou-du-Pont, S.; Scoul, C.; Colman, H.; Le Neel, T.; Le Houerou, C.; Faroux, R.; Ollivry, J.; Lafraise, B.; et al. Low-penetrance alleles predisposing to sporadic colorectal cancers: A French case-controlled genetic association study. BMC Cancer 2008, 8, 326. [Google Scholar] [CrossRef] [PubMed]
- Wilkening, S.; Tavelin, B.; Canzian, F.; Enquist, K.; Palmqvist, R.; Altieri, A.; Hallmans, G.; Hemminki, K.; Lenner, P.; Forsti, A. Interleukin promoter polymorphisms and prognosis in colorectal cancer. Carcinogenesis 2008, 29, 1202–1206. [Google Scholar] [CrossRef]
- Vogel, U.; Christensen, J.; Dybdahl, M.; Friis, S.; Hansen, R.D.; Wallin, H.; Nexo, B.A.; Raaschou-Nielsen, O.; Andersen, P.S.; Overvad, K.; et al. Prospective study of interaction between alcohol, NSAID use and polymorphisms in genes involved in the inflammatory response in relation to risk of colorectal cancer. Mutat. Res. 2007, 624, 88–100. [Google Scholar] [CrossRef]
- Theodoropoulos, G.; Papaconstantinou, I.; Felekouras, E.; Nikiteas, N.; Karakitsos, P.; Panoussopoulos, D.; Lazaris, A.; Patsouris, E.; Bramis, J.; Gazouli, M. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J. Gastroenterol. 2006, 12, 5037–5043. [Google Scholar] [CrossRef]
- Landi, S.; Moreno, V.; Gioia-Patricola, L.; Guino, E.; Navarro, M.; de Oca, J.; Capella, G.; Canzian, F.; Bellvitge Colorectal Cancer Study, G. Association of common polymorphisms in inflammatory genes interleukin (IL)6, IL8, tumor necrosis factor alpha, NFKB1, and peroxisome proliferator-activated receptor gamma with colorectal cancer. Cancer Res. 2003, 63, 3560–3566. [Google Scholar]
- Burz, C.; Bojan, A.; Balacescu, L.; Pop, V.V.; Silaghi, C.; Lupan, I.; Aldea, C.; Sur, D.; Samasca, G.; Cainap, C.; et al. Interleukin 8 as predictive factor for response to chemotherapy in colorectal cancer patients. Acta Clin. Belg. 2021, 76, 113–118. [Google Scholar] [CrossRef]
- Komura, T.; Yano, M.; Miyake, A.; Takabatake, H.; Miyazawa, M.; Ogawa, N.; Seki, A.; Honda, M.; Wada, T.; Matsui, S.; et al. Immune Condition of Colorectal Cancer Patients Featured by Serum Chemokines and Gene Expressions of CD4+ Cells in Blood. Can. J. Gastroenterol. Hepatol. 2018, 2018, 7436205. [Google Scholar] [CrossRef]
- Oladipo, O.; Conlon, S.; O’Grady, A.; Purcell, C.; Wilson, C.; Maxwell, P.J.; Johnston, P.G.; Stevenson, M.; Kay, E.W.; Wilson, R.H.; et al. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br. J. Cancer 2011, 104, 480–487. [Google Scholar] [CrossRef] [PubMed]
- Xia, W.; Chen, W.; Zhang, Z.; Wu, D.; Wu, P.; Chen, Z.; Li, C.; Huang, J. Prognostic value, clinicopathologic features and diagnostic accuracy of interleukin-8 in colorectal cancer: A meta-analysis. PLoS ONE 2015, 10, e0123484. [Google Scholar] [CrossRef] [PubMed]
Figure 1.
The physical map of the four IL-8 polymorphic sites investigated in this study.
Figure 2.
The genotype–phenotype correlation of IL-8 rs4073. Correlation between the IL-8 rs4073 genotype and IL-8 expression in the serum of healthy subjects. (A) comparing three different genotypes; (B) comparing TT and AT + AA genotypes. * Statistically significantly different from TT genotypes; # Statistically significantly different from AT genotypes. TT: TT genotype carriers; AT: AA genotype carriers; AA: AA genotype carriers.
Figure 2.
The genotype–phenotype correlation of IL-8 rs4073. Correlation between the IL-8 rs4073 genotype and IL-8 expression in the serum of healthy subjects. (A) comparing three different genotypes; (B) comparing TT and AT + AA genotypes. * Statistically significantly different from TT genotypes; # Statistically significantly different from AT genotypes. TT: TT genotype carriers; AT: AA genotype carriers; AA: AA genotype carriers.
Table 1.
The sequences of primer pairs for genotyping and RT-PCR.
| Polymorphic Sites | Primers |
|---|---|
| Genotyping | |
| rs4073 | F: 5′-TCATCCATGATCTTGTTCTA-3′ R: 5′-GGAAAACGCTGTAGGTCAGA-3′ |
| rs2227306 | F: 5′-CTCTAACTCTTTATATAGGA-3′ R: 5′-GATTGATTTTATCAACAGGC-3′ |
| rs2227543 | F: 5′-CTGATGGAAGAGAGCTCTGT-3′ R: 5′-TGTTAGAAATGCTCTATATT-3′ |
| rs1126647 | F: 5’-CCAGTTAAATTTTCATTTCA-3’ R: 5’-CAACCAGCAAGAAATTACTA-3’ |
| RT-PCR | |
| IL-8 | F: 5′-AAACCACCGGAAGGAACCAT-3′ R: 5′-GCCAGCTTGGAAGTCATGT-3′ |
| GAPDH | F: 5′-GAAATCCCATCACCATCTTCCAGG-3′ R: 5′-GAGCCCCAGCCTTCTCCATG-3′ |
F: Forward; R: reverse; RT-PCR: reverse transcription-polymerase chain reaction.
Table 2.
Selected characteristics of the 362 CRC patients and 362 non-cancer controls.
| Characteristic | Controls, n = 362 | Cases, n = 362 | p-Value a | ||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Age (years) | |||||
| ≤60 | 95 | 26.2% | 95 | 26.2% | 1.0000 |
| >60 | 267 | 73.8% | 267 | 73.8% | |
| Gender | |||||
| Male | 203 | 56.1% | 203 | 56.1% | 1.0000 |
| Female | 159 | 43.6% | 159 | 43.9% | |
| Smoking | |||||
| Yes | 84 | 23.2% | 91 | 25.1% | 0.5434 |
| No | 278 | 76.8% | 271 | 74.9% | |
| Alcohol drinking | |||||
| Yes | 51 | 14.1% | 44 | 12.2% | 0.4410 |
| No | 311 | 85.9% | 318 | 87.8% | |
| BMI | |||||
| <24 | 175 | 48.3% | 193 | 53.3% | 0.1809 |
| ≥24 | 187 | 51.7% | 169 | 46.7% | |
| Tumor size (cm) | |||||
| <5 | 195 | 53.9% | |||
| ≥5 | 167 | 46.1% | |||
| Location | |||||
| Colon | 257 | 71.0% | |||
| Rectum | 105 | 29.0% | |||
| Lymph node involvement | |||||
| Negative | 210 | 58.0% | |||
| Positive | 152 | 42.0% | |||
| Stage | |||||
| 1 | 94 | 26.0% | |||
| 2 | 72 | 19.9% | |||
| 3 | 134 | 37.0% | |||
| 4 | 62 | 17.1% | |||
SD, Standard deviation; BMI, body mass index; a based on the Chi-square test with Yates’ correction.
Table 3.
Associations between IL-8 genotypes and the risk of CRC in Taiwan.
| SNP | Genotype | Cases | Controls | p-Value | OR (95% CI) |
|---|---|---|---|---|---|
| rs4073 | TT | 102 (28.2%) | 128 (35.3%) | 1.00 (Ref) | |
| AT | 162 (44.7%) | 170 (47.0%) | 0.3407 | 1.20 (0.85–1.68) | |
| AA | 98 (27.1%) | 64 (17.7%) | 0.0023 * | 1.92 (1.28–2.89) | |
| Ptrend | 0.0059 * | ||||
| AT + AA | 260 (71.8%) | 234 (64.7%) | 0.0460 * | 1.39 (1.02–1.91) | |
| rs2227306 | CC | 144 (39.8%) | 131 (36.2%) | 1.00 (Ref) | |
| CT | 162 (44.8%) | 165 (45.6%) | 0.5431 | 0.89 (0.65–1.23) | |
| TT | 56 (15.4%) | 66 (18.2%) | 0.2804 | 0.77 (0.50–1.18) | |
| Ptrend | 0.4815 | ||||
| CT + TT | 218 (60.2%) | 231 (63.8%) | 0.3582 | 0.86 (0.64–1.16) | |
| rs2227543 | CC | 113 (31.2%) | 122 (33.7%) | 1.00 (Ref) | |
| CT | 165 (45.6%) | 163 (45.0%) | 0.6643 | 1.09 (0.78–1.53) | |
| TT | 84 (23.2%) | 77 (21.3%) | 0.4858 | 1.18 (0.79–1.76) | |
| Ptrend | 0.7185 | ||||
| CT + TT | 249 (68.8%) | 240 (66.3%) | 0.5254 | 1.12 (0.82–1.53) | |
| rs1126647 | AA | 127 (35.1%) | 122 (33.7%) | 1.00 (Ref) | |
| AT | 169 (46.7%) | 171 (47.2%) | 0.8198 | 0.95 (0.68–1.32) | |
| TT | 66 (18.2%) | 69 (19.1%) | 0.7726 | 0.92 (0.60–1.40) | |
| Ptrend | 0.9145 | ||||
| AT + TT | 235 (64.9%) | 240 (66.3%) | 0.7543 | 0.94 (0.69–1.28) |
OR: Odds ratio; CI: confidence interval; p-Values were calculated using the Chi-square test with Yates’ correction; HWE: Hardy–Weinberg Equilibrium; Ptrend, p-Value for trend analysis; *: p < 0.05; the significant values are marked in bold.
Table 4.
Associations of IL-8 alleles with the risk of CRC.
| Allele | Cases | Controls | p-Value | OR (95% CI) |
|---|---|---|---|---|
| rs4073 | ||||
| T | 366 (50.6%) | 426 (58.8%) | 1.00 (Ref) | |
| A | 358 (49.4%) | 298 (41.2%) | 0.0018 * | 1.40 (1.14–1.72) |
| rs2227306 | ||||
| C | 427 (59.0%) | 450 (62.2%) | 1.00 (Ref) | |
| T | 297 (41.0%) | 274 (37.8%) | 0.2368 | 1.14 (0.93–1.41) |
| rs2227543 | ||||
| C | 407 (56.2%) | 391 (54.0%) | 1.00 (Ref) | |
| T | 317 (43.8%) | 333 (46.0%) | 0.4280 | 0.91 (0.74–1.13) |
| rs1126647 | ||||
| A | 415 (57.3%) | 423 (58.4%) | 1.00 (Ref) | |
| T | 309 (42.7%) | 301 (41.6%) | 0.7095 | 1.05 (0.85–1.29) |
p-Value was calculated using the Chi-square test with Yates’ correction; *: p < 0.05; the significant values are marked in bold.
Table 5.
Associations between IL-8 rs4073 genotypes and the risk of CRC in stratified analyses.
| Genotype | Controls | Cases | OR (95% CI) a | aOR (95% CI) b | p-Value |
|---|---|---|---|---|---|
| Age | |||||
| ≤60 years old | |||||
| TT | 32 | 26 | 1.00 (ref) | 1.00 (ref) | |
| AT | 45 | 43 | 1.17 (0.60–2.29) | 1.20 (0.63–2.23) | 0.7576 |
| AA | 18 | 26 | 1.78 (0.80–3.93) | 1.87 (0.83–3.76) | 0.2197 |
| >60 years old | |||||
| TT | 96 | 76 | 1.00 (ref) | 1.00 (ref) | |
| AT | 125 | 119 | 1.20 (0.81–1.80) | 1.29 (0.78–1.94) | 0.4105 |
| AA | 46 | 72 | 1.98 (1.23–3.19) | 2.06 (1.27–3.36) | 0.0070 * |
| Gender | |||||
| Males | |||||
| TT | 69 | 55 | 1.00 (ref) | 1.00 (ref) | |
| AT | 96 | 91 | 1.19 (0.75–1.88) | 1.14 (0.79–1.79) | 0.5291 |
| AA | 38 | 57 | 1.88 (1.09–3.24) | 1.83 (1.14–3.08) | 0.0308 * |
| Females | |||||
| TT | 59 | 47 | 1.00 (ref) | 1.00 (ref) | |
| AT | 74 | 71 | 1.20 (0.73–1.99) | 1.16 (0.71–2.05) | 0.5503 |
| AA | 26 | 41 | 1.98 (1.06–3.69) | 2.09 (1.11–3.58) | 0.0451 * |
| Smoking behaviors | |||||
| Non-smokers | |||||
| TT | 94 | 71 | 1.00 (ref) | 1.00 (ref) | |
| AT | 133 | 122 | 1.21 (0.82–1.80) | 1.26 (0.84–1.93) | 0.3863 |
| AA | 51 | 78 | 2.02 (1.27–3.24) | 2.17 (1.32–2.98) | 0.0044 * |
| Smokers | |||||
| TT | 34 | 31 | 1.00 (ref) | 1.00 (ref) | |
| AT | 37 | 40 | 1.19 (0.61–2.30) | 1.24 (0.59–2.43) | 0.7362 |
| AA | 13 | 20 | 1.69 (0.72–3.95) | 1.76 (0.77–4.08) | 0.3195 |
| Alcohol drinking behaviors | |||||
| Non-drinkers | |||||
| TT | 101 | 84 | 1.00 (ref) | 1.00 (ref) | |
| AT | 150 | 144 | 1.15 (0.80–1.67) | 1.22 (0.84–1.96) | 0.5037 |
| AA | 60 | 90 | 1.80 (1.17–2.79) | 1.94 (1.19–2.93) | 0.0108 * |
| Drinkers | |||||
| TT | 27 | 18 | 1.00 (ref) | 1.00 (ref) | |
| AT | 20 | 18 | 1.35 (0.56–3.23) | 1.39 (0.58–3.37) | 0.6508 |
| AA | 4 | 8 | 3.00 (0.79–11.46) | 3.34 (0.73–8.65) | 0.1862 |
| BMI | |||||
| <24 | |||||
| TT | 57 | 49 | 1.00 (ref) | 1.00 (ref) | |
| AT | 81 | 86 | 1.24 (0.76–2.01) | 1.19 (0.71–2.04) | 0.4686 |
| AA | 37 | 58 | 1.82 (1.04–3.20) | 1.78 (1.14–2.95) | 0.0498 * |
| ≥24 | |||||
| TT | 71 | 53 | 1.00 (ref) | 1.00 (ref) | |
| AT | 89 | 76 | 1.14 (0.72–1.83) | 1.22 (0.70–2.29) | 0.6584 |
| AA | 27 | 40 | 1.98 (1.08–3.63) | 2.15 (1.24–3.88) | 0.0370 * |
a, by multivariate logistic regression analysis; b, by multivariate logistic regression analysis after the adjustments of confounding factors; CI, confidence interval; aOR, adjusted odds ratio. *: p < 0.05; the significant values are marked in bold.
Table 6.
Literature reports of the associations between IL-8 rs4073 genotypes and the risk of CRC.
| First Author | Year | Ethnicity | TT, AT, AA Genotype # of the Controls | TT, AT, AA Genotype # of the Cases | Highlights of the Findings | Ref # |
|---|---|---|---|---|---|---|
| Tsai | 2023 | Taiwanese | 128:170:64 | 102:162: 98 | AA genotype contributed to increased risk | current |
| Walczak | 2012 | Caucasian | 99:71:35 | 50:104:37 | AA genotype contributed to increased risk | [19] |
| Mustapha | 2012 | Mixed | 54: 189: 12 | 40:183:32 | AA genotype contributed to increased risk | [20] |
| Gunter | 2006 | Caucasian | 65:94:32 | 52:87:66 | AA genotype contributed to increased risk | [21] |
| Tsilidis | 2009 | Caucasian | 114:162:86 | 65:88:52 | No variant genotypes contributed to altered risk | [22] |
| Cacev | 2008 | Caucasian | 53:73:34 | 46:75:39 | No variant genotypes contributed to altered risk | [23] |
| Kury | 2008 | Caucasian | 375:516:230 | 307:511:205 | No variant genotypes contributed to altered risk | [24] |
| Wilkening | 2008 | Caucasian | 115:296:169 | 71:133:96 | No variant genotypes contributed to altered risk | [25] |
| Vogel | 2007 | Caucasian | 160:367:226 | 83:178:94 | No variant genotypes contributed to altered risk | [26] |
| Theodoropoulos | 2006 | Caucasian | 64:90:42 | 76:106:40 | No variant genotypes contributed to altered risk | [27] |
| Landi | 2003 | Caucasian | 117:167:68 | 83:170:55 | No variant genotypes contributed to altered risk | [28] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
MDPI and ACS Style
Tsai, C.-W.; Chang, W.-S.; Yueh, T.-C.; Wang, Y.-C.; Chin, Y.-T.; Yang, M.-D.; Hung, Y.-C.; Mong, M.-C.; Yang, Y.-C.; Gu, J.; et al. The Significant Impacts of Interleukin-8 Genotypes on the Risk of Colorectal Cancer in Taiwan. Cancers 2023, 15, 4921. https://doi.org/10.3390/cancers15204921
AMA Style
Tsai C-W, Chang W-S, Yueh T-C, Wang Y-C, Chin Y-T, Yang M-D, Hung Y-C, Mong M-C, Yang Y-C, Gu J, et al. The Significant Impacts of Interleukin-8 Genotypes on the Risk of Colorectal Cancer in Taiwan. Cancers. 2023; 15(20):4921. https://doi.org/10.3390/cancers15204921
Chicago/Turabian StyleTsai, Chia-Wen, Wen-Shin Chang, Te-Cheng Yueh, Yun-Chi Wang, Yu-Ting Chin, Mei-Due Yang, Yi-Chih Hung, Mei-Chin Mong, Ya-Chen Yang, Jian Gu, and et al. 2023. "The Significant Impacts of Interleukin-8 Genotypes on the Risk of Colorectal Cancer in Taiwan" Cancers 15, no. 20: 4921. https://doi.org/10.3390/cancers15204921
APA StyleTsai, C. -W., Chang, W. -S., Yueh, T. -C., Wang, Y. -C., Chin, Y. -T., Yang, M. -D., Hung, Y. -C., Mong, M. -C., Yang, Y. -C., Gu, J., & Bau, D. -T. (2023). The Significant Impacts of Interleukin-8 Genotypes on the Risk of Colorectal Cancer in Taiwan. Cancers, 15(20), 4921. https://doi.org/10.3390/cancers15204921
Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.
